For the Consumer
Applies to testosterone: buccal patch extended release
Along with its needed effects, testosterone may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking testosterone:
Get emergency help immediately if any of the following symptoms of overdose occur while taking testosterone:
Some side effects of testosterone may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to testosterone: buccal film extended release, compounding powder, intramuscular solution, nasal gel, subcutaneous implant, transdermal cream, transdermal film extended release, transdermal gel, transdermal ointment, transdermal solution
The most frequently reported side effects with this drug are edema, acne, site pain, injection site erythema, cough or dyspnea during or immediately after injection.
The most frequently reported side effects with testosterone topical are skin reaction (16.1%) and allergic contact dermatitis (up to 37%).[Ref]
Very common (10% or more): Testosterone topical: Skin reaction (16.1%), burn-like blisters (12%), itching, allergic contact dermatitis (up to 37%)Common (1% to 10%): Acne, induration, burningUncommon (0.1% to 1%): Alopecia, erythema, rash (including rash popular), pruritus, dry skin, folliculitis (testosterone topical)Frequency not reported: Seborrhea, urticaria, male pattern baldness, hirsutism injection site inflammationPostmarketing reports: Angioedema, angioneurotic edema, hyperhidrosis, discolored hair, leukocytoclastic vasculitis[Ref]
Very common (10% or more): Accelerated growthCommon (1% to 10%): Increased estradiol, hypogonadismUncommon (0.1% to 1%): Increased blood testosteroneFrequency not reported: Signs of virilization in women (e.g., hoarseness, acne, hirsutism, menstrual irregularity, clitoral enlargement, and alopecia), precocious puberty (in prepubertal males)Postmarketing reports: Hyperparathyroidism, prolactin increased, testosterone increased[Ref]
Very common (10% or more): Testosterone buccal film: Gingivitis (32.6%)Common (1% to 10%): Diarrhea, oily stools (due to IM injection oily solvent); Testosterone topical: Gastroesophageal reflux disease, gastrointestinal bleeding, gum or mouth irritation (9.2%), taste bitter, gum pain, gum tenderness, gum edema, taste perversionUncommon (0.1% to 1%): NauseaRare (less than 0.1%): Abdominal painFrequency not reported: Abdominal disorder, intraabdominal hemorrhagePostmarketing reports: Vomiting; Testosterone buccal film: Dry mouth, gingival swelling, lip swelling, mouth ulceration, stomatitis[Ref]
The majority of gum-related adverse events were transient.[Ref]
Very common (10% or more): Testosterone topical: Application site pruritus (up to 37%), application site blistering (12%)Common (1% to 10%): Injection site pain, injection site discomfort, injection site pruritus, erythema, injection site hematoma, injection site irritation, injection site inflammation; injection site reaction; Topical testosterone: Application site erythema, application site warmth, application site irritation, application site vesicles, application site exfoliation, application site burning, application site induration, bullae at application site, mechanical irritation at application site, rash at application site, contamination of application sitePostmarketing reports: Injection site abscess, procedural pain, application site swelling (topical testosterone)[Ref]
Common (1% to 10%): Hot flush, hypertensionUncommon (0.1% to 1%): Cardiovascular disorderFrequency not reported: Venous thromboembolismPostmarketing reports: Angina pectoris, cardiac arrest, cardiac failure, coronary artery disease, coronary artery occlusion, myocardial infarction, tachycardia, cerebral infarction, cerebrovascular accident, circulatory collapse, deep venous thrombosis, syncope, thromboembolism, thrombosis, venous insufficiency, stroke[Ref]
Common (1% to 10%): Abnormal prostate examination, benign prostate hyperplasia (BPH), ejaculation disorder, prostatitisUncommon (0.1% to 1%): Prostate induration, prostatic disorder, testicular pain, decreased urine flow, urinary retention, urinary tract disorder, nocturia, dysuriaRare (less than 0.1%): Micturition disorders, epididymitis, bladder irritability, impotence, inhibition of testicular function and testicular atrophyFrequency not reported: Oligospermia, priapism, benign prostatic hyperplasia (prostatic growth to eugonadal state), excessive frequency and duration of erections; Pediatrics: Precocious sexual development, an increased frequency of erections, phallic enlargementPostmarketing reports: Prostate infection, calculus urinary, dysuria, hematuria, urinary tract disorder, pollakiuria[Ref]
Common (1% to 10%): Polycythemia, hematocrit increasedUncommon (0.1% to 1%): Increased red blood cell count, increased hemoglobin, prolonged activated partial thromboplastin time, prolonged prothrombin timeFrequency not reported: Blood and lymphatic system disorders, suppression of clotting factors II, V, VII, and X, bleeding in patients on concomitant anticoagulant therapyPostmarketing reports: Thrombocytopenia, anemia[Ref]
Common (1% to 10%): Weight increased, appetite increased, fluid retention (sodium, chloride, water, potassium, calcium, and inorganic phosphates)Uncommon (0.1% to 1%): Increased glycosylated hemoglobin, hypercholesterolemia, increased triglycerideFrequency not reported: Abnormal lipids (decrease in serum LDL, HDL, and triglycerides), metabolism and nutrition disorders, hypercalcemiaPostmarketing reports: Hypoglycemia, diabetes mellitus, fluid retention, hyperlipidemia, hypertriglyceridemia, blood glucose increased[Ref]
Common (1% to 10%): Back pain, hemarthrosis (testosterone topical)Uncommon (0.1% to 1%): Arthralgia, pain in extremity, muscle spasm, muscle strain, myalgia, musculoskeletal stiffness, increased creatine phosphokinaseFrequency not reported: Pediatrics: Premature epiphyseal closure, increased bone formationPostmarketing reports: Musculoskeletal chest pain, musculoskeletal pain, myalgia, osteopenia, osteoporosis, systemic lupus erythematosus[Ref]
Common (1% to 10%): Headache, vertigo (topical testosterone)Uncommon (0.1% to 1%): Migraine, tremor, dizzinessFrequency not reported: Nervousness, paresthesiaPostmarketing reports: Cerebrovascular insufficiency, reversible ischemic neurological deficiency, transient ischemic attack, amnesia[Ref]
Common (1% to 10%): Prostatic specific antigen (PSA) increased, prostate cancerUncommon (0.1% to 1%): Prostatic intraepithelial neoplasiaRare (less than 0.1%): Neoplasms benign, malignant, and unspecified (including cysts and polyps)[Ref]
Common (1% to 10%): Fatigue, hyperhidrosis; chills, body pain, smell disorderUncommon (0.1% to 1%): Breast induration, breast pain, sensitive nipples, gynecomastia, increased estradiol, increased testosterone, asthenia, night sweats Rare (less than 0.1%): Fever, malaiseFrequency not reported: EdemaPostmarketing reports: Sudden hearing loss, tinnitus, Influenza like illness[Ref]
Common (1% to 10%): Irritability, insomnia, mood swings, aggression,Uncommon (0.1% to 1%): Depression, emotional disorder, restlessness, increased libido, decreased libidoFrequency not reported: Hostility, anxietyPostmarketing reports: Korsakoff’s psychosis nonalcoholic, male orgasmic disorder, restlessness, sleep disorder[Ref]
Common (1% to 10%): Sinusitis, nasopharyngitis, upper respiratory tract infection, bronchitisUncommon (0.1% to 1%): Cough, dyspnea, snoring, dysphoniaRare (less than 0.1%): Pulmonary microembolism (POME) (cough, dyspnea, malaise, hyperhidrosis, chest pain, dizziness, paresthesia, or syncope) caused by oily solutionsFrequency not reported: Sleep apneaPostmarketing reports: Chest pain, asthma, chronic obstructive pulmonary disease, hyperventilation, obstructive airway disorder, pharyngeal edema, pharyngolaryngeal pain, pulmonary embolism, respiratory distress, rhinitis, sleep apnea syndrome[Ref]
Signs and symptoms of pulmonary microemboli may occur during or immediately after the injections and are reversible.[Ref]
Uncommon (0.1% to 1%): Abnormal LFT, increased ASTRare (less than 0.1%): Abnormal hepatic functionFrequency not reported: Jaundice, benign liver tumor, malignant liver tumor, liver enlargement, peliosis hepatitisPostmarketing reports: ALT increased, AST increased, bilirubin increased, transaminases increased, gamma-glutamyltransferase increased[Ref]
Uncommon (0.1% to 1%): Hypersensitivity reactionsFrequency not reported: Anaphylactic reactionsPostmarketing reports: Anaphylactic shock[Ref]
Uncommon (0.1% to 1%): Testosterone topical: Lacrimation increasedPostmarketing reports: Testosterone topical: Intraocular pressure increased, vitreous detachment[Ref]
Postmarketing reports: Nephrolithiasis, renal colic, renal pain[Ref]
1. “Product Information. Fortesta (testosterone).” Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.
2. “Product Information. AndroGel (testosterone).” Unimed Pharmaceuticals, Buffalo Grove, IL.
3. Cerner Multum, Inc. “Australian Product Information.” O 0
4. “Product Information. Testosterone Enanthate (testosterone).” West-Ward Pharmaceutical Corporation, Eatontown, NJ.
5. Cerner Multum, Inc. “UK Summary of Product Characteristics.” O 0
6. “Product Information. Axiron (testosterone).” Lilly, Eli and Company, Indianapolis, IN.
7. “Product Information. Testopel (testosterone).” Bartor Pharmacal Co, Inc, Rye, NY.
8. “Product Information. Aveed (testosterone).” Endo Pharmaceuticals Solutions Inc, Malvern, PA.
9. “Product Information. Testim (testosterone).” A-S Medication Solutions, Chicago, IL.
10. “Product Information. Androderm (testosterone topical).” SmithKline Beecham, Philadelphia, PA.
11. “Product Information. Depo-Testosterone (testosterone).” Pfizer U.S. Pharmaceuticals Group, New York, NY.
12. Bates GW, Cornwell CE “Iatrogenic causes of hirsutism.” Clin Obstet Gynecol 34 (1991): 848-51
13. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA “Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men.” J Clin Endocrinol Metab 84 (1999): 3469-78
14. O’Driscoll JB, August PJ “Exacerbation of psoriasis precipitated by an oestradiol-testosterone implant.” Clin Exp Dermatol 15 (1990): 68-9
15. Fyrand O, Fiskaadal HJ, Trygstad O “Acne in pubertal boys undergoing treatment with androgens.” Acta Derm Venereol 72 (1992): 148-9
16. Traupe H, von Muhlendahl KE, Bramswig J, Happle R “Acne of the fulminans type following testosterone therapy in three excessively tall boys.” Arch Dermatol 124 (1988): 414-7
17. Wu FC, Farley TM, Peregoudov A, Waites GM “Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organizatio Task Force on Methods for the Regulation of Male Fertility.” Fertil Steril 65 (1996): 626-36
18. Bennett NJ “A burn-like lesion caused by a testosterone transdermal system.” Burns 24 (1998): 478-80
19. Buckley DA, Wilkinson SM, Higgins EM “Contact allergy to a testosterone patch.” Contact Dermatitis 39 (1998): 91-2
20. DeSanctis V, Vullo C, Urso L, Rigolin F, Cavallini A, Caramelli K, Daugherty C, Mazer N “Clinical experience using the Androderm (R) testosterone transdermal system in hypogonadal adolescents and young men with beta-thalassemia major.” J Pediatr Endocrinol Metab 11 (1998): 891-900
21. Cefalu WT, Pardridge WM, Premachandra BN “Hepatic bioavailability of thyroxine and testosterone in familial dysalbuminemic hyperthyroxinemia.” J Clin Endocrinol Metab 61 (1985): 783-6
22. Matsumoto AM “Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.” J Clin Endocrinol Metab 70 (1990): 282-7
23. Tripathy D, Shah P, Lakshmy R, Reddy KS “Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathi hypogonadotrophic hypogonadism.” Horm Metab Res 30 (1998): 642-5
24. Becker U, Gluud C, Bennett P “The effect of oral testosterone on serum TBG levels in alcoholic cirrhotic men.” Liver 8 (1988): 219-24
25. Ferrera PC, Putnam DL, Verdile VP “Anabolic steroid use as the possible precipitant of dilated cardiomyopathy.” Cardiology 88 (1997): 218-20
26. Jackson JA, Waxman J, Spiekerman AM “Prostatic complications of testosterone replacement therapy.” Arch Intern Med 149 (1989): 2365-6
27. Zelissen PM, Stricker BH “Severe priapism as a complication of testosterone substitution therapy.” Am J Med 85 (1988): 273-4
28. Wang C, Leung A, Superlano L, Steiner B, Swerdloff RS “Oligozoospermia induced by exogenous testosterone is associated with normal functioning residual spermatozoa.” Fertil Steril 68 (1997): 149-53
29. Endres W, Shin YS, Rieth M, Block T, Schmiedt E, Knorr D “Priapism in Fabry’s disease during testosterone treatment.” Klin Wochenschr 65 (1987): 925
30. Parker LU, Bergfeld WF “Virilization secondary to topical testosterone.” Cleve Clin J Med 58 (1991): 43-6
31. Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ “A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men.” J Clin Endocrinol Metab 84 (1999): 3642-7
32. Anderson FH, Francis RM, Faulkner K “Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascula risk factors.” Bone 18 (1996): 171-7
33. Bhasin S, Storer TW, Javanbakht M, et al. “Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels.” JAMA 283 (2000): 763-70
34. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ “Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men.” J Clin Endocrinol Metab 79 (1994): 561-7
35. Lajarin F, Zaragoza R, Tovar I, Martinezhernandez P “Evolution of serum lipids in two male bodybuilders using anabolic steroids.” Clin Chem 42 (1996): 970-2
36. Zmuda JM, Thompson PD, Dickenson R, Bausserman LL “Testosterone decreases lipoprotein(a) in men.” Am J Cardiol 77 (1996): 1244
37. Stannard JP, Bucknell AL “Rupture of the triceps tendon associated with steroid injections.” Am J Sports Med 21 (1993): 482-5
38. Pollard M “Tumorigenic effect of testosterone.” Lancet 336 (1990): 1518
39. Uzych L “Anabolic-androgenic steroids and psychiatric-related effects: a review.” Can J Psychiatry 37 (1992): 23-8
40. Nuzzo JL, Manz HJ, Maxted WC “Peliosis hepatis after long-term androgen therapy.” Urology 25 (1985): 518-9
41. Carrasco D, Prieto M, Pallardo L, Moll JL, Cruz JM, Munoz C, Berenguer J “Multiple hepatic adenomas after long-term therapy with testosterone enanthate. Review of the literature.” J Hepatol 1 (1985): 573-8
42. Yu MW, Chen CJ “Elevated serum testosterone levels and risk of hepatocellular carcinoma.” Cancer Res 53 (1993): 790-4
43. Falk H, Thomas LB, Popper H, Ishak KG “Hepatic angiosarcoma associated with androgenic-anabolic steroids.” Lancet 2 (1979): 1120-3
Some side effects of testosterone may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.
Go here to read the rest:
Testosterone Side Effects in Detail – Drugs.com